US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Cocrystal Pharma Inc (COCP)
Cocrystal Pharma Inc (COCP) ニュース

COCP

Cocrystal Pharma (COCP)

Cocrystal Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:COCP

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/08	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2025/01/08	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections	NASDAQ:COCP	Cocrystal Pharma Inc
2024/12/31	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/12/31	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344	NASDAQ:COCP	Cocrystal Pharma Inc
2024/11/14	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/11/13	22 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COCP	Cocrystal Pharma Inc
2024/11/13	22 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	NASDAQ:COCP	Cocrystal Pharma Inc
2024/10/31	22 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/10/31	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins	NASDAQ:COCP	Cocrystal Pharma Inc
2024/10/12	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COCP	Cocrystal Pharma Inc
2024/10/12	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COCP	Cocrystal Pharma Inc
2024/10/12	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COCP	Cocrystal Pharma Inc
2024/10/12	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:COCP	Cocrystal Pharma Inc
2024/10/11	06 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/09/26	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts	NASDAQ:COCP	Cocrystal Pharma Inc
2024/08/20	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/08/20	05 : 05	GlobeNewswire Inc.	Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences	NASDAQ:COCP	Cocrystal Pharma Inc
2024/08/14	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/08/14	21 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COCP	Cocrystal Pharma Inc
2024/08/14	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	NASDAQ:COCP	Cocrystal Pharma Inc
2024/07/18	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/07/18	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor	NASDAQ:COCP	Cocrystal Pharma Inc
2024/06/20	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/06/20	21 : 00	GlobeNewswire Inc.	New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/13	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/13	21 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/13	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/08	05 : 30	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:COCP	Cocrystal Pharma Inc
2024/05/01	21 : 00	GlobeNewswire Inc.	Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza	NASDAQ:COCP	Cocrystal Pharma Inc
2024/03/28	21 : 00	GlobeNewswire Inc.	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	NASDAQ:COCP	Cocrystal Pharma Inc

Showing the most relevant articles for your search:NASDAQ:COCP

1 2 3 4 5 6 7 8 9 10 次へ >>

Action Logement Services...

Compagnie d`Entreprises ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約